Business

Viking Therapeutics shares rise after Madrigal shares positive data on liver disease drug


Shares of Viking Therapeutics Inc.
VKTX,
+73.88 %

saw a 55% increase in premarketing on Monday after a company was also developing a beta-selective thyroid hormone receptor agonist to treat non-alcoholic steatohepatitis (NASH) and cirrhosis. has published positive data in the late stages. Madrigal pharmaceutical company
MDGL,
+268.07%

said Monday it is aiming to gain rapid approval in the United States for its drug. The “treatment candidate” is currently in a Phase 2b clinical trial. The company’s shares are down 24.7% year-to-date, while the broader S&P 500 index
SPX,
-0.90%

fell 19.1%.

news7f

News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, Sports...at the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button